By Lauraann Wood ( August 8, 2022, 11:03 PM EDT) -- An Illinois federal judge on Saturday refused to unwind Actavis' trial win over allegations that the company's Androderm testosterone drug caused a man's heart attack, saying that while Actavis' disclosure of a regulator's letter hours after trial was "fishy," the plaintiff had not proved the company needed to share it earlier....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.